Our retrospective analysis revealed significant short-term improvements in glycemic control (within 6 months), consistent with findings from several prospective and retrospective studies.[11,28] Moreover, mendelian randomization results also suggest that CXCL10 may be a critical target for DAAs in improving diabetes. The gene discussed is CXCL10; the disease is diabetes mellitus.